Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-11-14
|
ONS-3010 (biosimilar version of Humira® (adalimumab)) |
|
1 |
Oncobiologics (USA - NJ) |
Autoimmune diseases |
2016-11-14
|
sacituzumab govitecan - IMMU-132 |
epithelial cancers including triple-negative breast cancer, non-small cell lung cancer, small-cell lung cancer |
2 |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-11-13
|
inclisiran (ALN-PCSsc) |
hypercholesterolemia |
1 |
Alnylam Pharmaceuticals (USA - MA) The Medicines Company (USA - NJ) |
Cardiovascular diseases - Metabolic diseases |
2016-11-12
|
romosozumab (CDP7851/AMG 785) |
osteoporosis in men |
3 |
Amgen (USA - CA) UCB (Belgium) |
Bone diseases |
2016-11-11
|
dabigatran etexilate |
non-valvular atrial fibrillation |
3 |
Boehringer Ingelheim (Germany) |
Cardiovascular diseases |
2016-11-11
|
aldoxorubicin |
soft tissue sarcoma |
1b-2 |
CytRx Corporation (USA - CA) |
Cancer - Oncology |
2016-11-11
|
migalastat |
Fabry disease |
3 |
Amicus Therapeutics (USA - NJ) |
Rare diseases - Genetic diseases |
2016-11-11
|
sebelipase alfa |
lysosomal acid lipase deficiency (LAL Deficiency) |
3 |
Synageva BioPharma (USA - MA), now Alexion Pharmaceuticals (USA - CT) |
Rare diseases |
2016-11-10
|
blisibimod |
systemic lupus erythematosus (SLE) |
3 |
Anthera Pharmaceuticals (USA - CA) |
Autoimmune diseases |
2016-11-10
|
custirsen |
non-small cell lung cancer (NSCLC) |
3 |
OncoGenex Pharmaceuticals (USA - WA) |
Cancer - Oncology |
2016-11-10
|
custirsen (OGX-011) |
prostate cancer |
3 |
OncoGenex Pharmaceuticals (USA - WA) |
Cancer - Oncology |
2016-11-10
|
GLS-5700 |
Zika virus infection |
preclinical |
Inovio Pharmaceuticals (USA - PA) |
Infectious diseases |
2016-11-10
|
daratumumab, carfilzomib and dexamethasone |
patients with multiple myeloma who have received one to three prior therapies |
3 |
Amgen (USA - CA) Janssen Biotech, a J&J company (USA - NJ) |
Cancer - Oncology |
2016-11-09
|
ARC-520 |
hepatitis B |
2 |
Arrowhead Pharmaceuticals (USA - CA) |
Infectious diseases |
2016-11-09
|
CA-170 |
advanced solid tumors, lymphoma |
1 |
Curis (USA - MA) |
Cancer - Oncology |
2016-11-08
|
Adcetris® (brentuximab vedotin) |
CD30-positive mature T-cell lymphoma (MTCL) |
3 |
Millenium Pharmaceuticals (USA - MA) Seattle Genetics (USA - WA), wholly owned subsidiaries of Takeda Pharmaceutical (Japan) |
Cancer - Oncology |
2016-11-08
|
mRNA-encoded antibodies, RNAntibody® technology. |
|
preclinical |
Curevac (Germany) |
|
2016-11-08
|
Viaskin® Milk |
cow milk allergy |
2 |
DBV Technologies (France) |
Allergic diseases |
2016-11-07
|
macitentan |
chronic thromboembolic pulmonary hypertension |
2 |
Actelion (Switzerland) |
Rare diseases - Cardiovascular diseases - Respiratory diseases |
2016-11-07
|
IFN alpha-Kinoid |
systemic lupus erythematosus |
2b |
Neovacs (France) |
Autoimmune diseases - Dermatological diseases - Inflammatory diseases |